Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Erhan Ararat

Concepts (111)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
11
2015
1201
1.080
Why?
Organoids
2
2022
36
0.960
Why?
Anti-Asthmatic Agents
1
2023
29
0.860
Why?
Asthma
2
2024
284
0.850
Why?
Metformin
1
2023
65
0.810
Why?
Lung
3
2022
504
0.720
Why?
Aspirin
2
2011
112
0.650
Why?
Cystic Fibrosis
1
2021
147
0.630
Why?
Diabetes Mellitus
1
2021
279
0.580
Why?
Neoadjuvant Therapy
3
2013
120
0.450
Why?
Antineoplastic Combined Chemotherapy Protocols
3
2011
1000
0.350
Why?
Diphosphonates
1
2010
90
0.330
Why?
Imidazoles
1
2010
127
0.330
Why?
Neoplasm Metastasis
1
2010
232
0.330
Why?
Protein Phosphatase 1
1
2009
7
0.320
Why?
Adolescent
5
2024
6443
0.320
Why?
Losartan
1
2009
27
0.320
Why?
Mitogen-Activated Protein Kinase 3
1
2009
49
0.320
Why?
Mitogen-Activated Protein Kinase 1
1
2009
50
0.320
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2010
121
0.320
Why?
Angiotensin II Type 1 Receptor Blockers
1
2009
43
0.320
Why?
Isoenzymes
1
2009
168
0.310
Why?
MAP Kinase Signaling System
1
2009
117
0.310
Why?
Genetic Predisposition to Disease
1
2011
511
0.290
Why?
Child
4
2024
6906
0.290
Why?
Humans
20
2024
50503
0.250
Why?
Antineoplastic Agents
2
2011
1172
0.250
Why?
Allergy and Immunology
1
2024
19
0.230
Why?
Female
15
2024
27081
0.210
Why?
Adrenal Cortex Hormones
1
2023
99
0.210
Why?
Preoperative Care
1
2024
169
0.200
Why?
Home Care Services
1
2023
73
0.200
Why?
Spinocerebellar Ataxias
1
2022
4
0.200
Why?
Medicaid
1
2024
252
0.200
Why?
Young Adult
4
2023
4102
0.190
Why?
Body Height
1
2021
64
0.180
Why?
Mass Screening
1
2024
344
0.180
Why?
Respiration, Artificial
1
2023
296
0.180
Why?
Anthracyclines
2
2011
29
0.180
Why?
Nutritional Status
1
2021
136
0.180
Why?
Disease Progression
1
2023
829
0.180
Why?
Incidence
2
2011
1032
0.140
Why?
Child, Preschool
2
2024
3942
0.130
Why?
Retrospective Studies
4
2024
6263
0.130
Why?
Adult
5
2023
13577
0.130
Why?
Multiple Myeloma
1
2010
2998
0.130
Why?
Muscular Dystrophy, Duchenne
1
2015
24
0.120
Why?
Receptors, Progesterone
2
2013
64
0.110
Why?
Receptor, erbB-2
2
2013
75
0.110
Why?
Cardiomyopathies
1
2015
120
0.110
Why?
Receptors, Estrogen
2
2013
132
0.110
Why?
Axilla
1
2013
91
0.100
Why?
Male
5
2024
25907
0.100
Why?
Prognosis
3
2015
1978
0.100
Why?
Heart
1
2015
341
0.100
Why?
Lymphatic Metastasis
1
2013
222
0.100
Why?
Phenotype
1
2015
739
0.100
Why?
Survival Rate
2
2013
909
0.100
Why?
Dacarbazine
1
2011
10
0.090
Why?
Opportunistic Infections
1
2011
57
0.090
Why?
Lymph Nodes
1
2013
257
0.090
Why?
Deoxycytidine
1
2011
30
0.090
Why?
Antineoplastic Agents, Alkylating
1
2011
73
0.090
Why?
Fluorouracil
1
2011
58
0.090
Why?
Genes, BRCA1
1
2011
19
0.090
Why?
Phthalazines
1
2011
20
0.090
Why?
Drugs, Generic
1
2010
6
0.090
Why?
Neoplasm Recurrence, Local
2
2013
629
0.090
Why?
Taxoids
1
2010
37
0.090
Why?
Tamoxifen
1
2010
60
0.090
Why?
Antineoplastic Agents, Hormonal
1
2010
49
0.090
Why?
Piperazines
1
2011
119
0.080
Why?
Captopril
1
2009
13
0.080
Why?
Angiotensin-Converting Enzyme Inhibitors
1
2009
74
0.080
Why?
p38 Mitogen-Activated Protein Kinases
1
2009
93
0.080
Why?
Chemotherapy, Adjuvant
3
2015
121
0.080
Why?
Enzyme Activation
1
2009
268
0.080
Why?
Muscle, Smooth, Vascular
1
2009
131
0.070
Why?
Aorta
1
2009
163
0.070
Why?
Ventricular Function, Left
1
2009
169
0.070
Why?
Age Factors
1
2011
1110
0.070
Why?
Follow-Up Studies
1
2011
2242
0.060
Why?
Rats, Sprague-Dawley
1
2009
1585
0.060
Why?
Myocardial Infarction
1
2009
403
0.060
Why?
Apoptosis
1
2010
1097
0.060
Why?
Mutation
1
2011
1280
0.060
Why?
Treatment Outcome
2
2013
5283
0.060
Why?
Respiration
1
2023
99
0.050
Why?
Heart Failure
1
2009
528
0.050
Why?
Tracheostomy
1
2023
71
0.050
Why?
Rats
1
2009
3292
0.050
Why?
Animals
2
2022
13124
0.050
Why?
Stem Cells
1
2022
166
0.050
Why?
Emergency Service, Hospital
1
2024
484
0.040
Why?
Epithelial Cells
1
2022
207
0.040
Why?
Hospitalization
1
2024
675
0.040
Why?
Cell Differentiation
1
2022
640
0.040
Why?
Arkansas
1
2024
1985
0.040
Why?
Infant
1
2024
3628
0.030
Why?
Respiratory Function Tests
1
2015
86
0.030
Why?
Aged
3
2013
9741
0.030
Why?
United States
1
2024
4955
0.030
Why?
Neoplasm Invasiveness
1
2013
269
0.020
Why?
Disease-Free Survival
1
2013
444
0.020
Why?
Mice
1
2022
5687
0.020
Why?
Chemistry, Pharmaceutical
1
2010
33
0.020
Why?
Arthralgia
1
2010
45
0.020
Why?
Drug Administration Schedule
1
2010
370
0.020
Why?
Middle Aged
2
2013
12611
0.020
Why?
Risk Factors
1
2015
3724
0.020
Why?
Aged, 80 and over
1
2013
3226
0.020
Why?
Ararat's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description